Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CD73 expression
i
Other names:
CD73, 5'-Nucleotidase Ecto, Ecto-5'-Nucleotidase, 5'-Nucleotidase, 5'-NT, NT5, NTE, 5'-Nucleotidase, Ecto (CD73), Purine 5-Prime-Nucleotidase, 5' Nucleotidase (CD73), CD73 Antigen, E5NT
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4907
Related biomarkers:
Expression
Others
‹
›
Associations
(2)
News
Trials
Search handles
@StephenVLiu
@montypal
Search handles
@StephenVLiu
@montypal
Filter by
Latest
9ms
What do we know about resistance to durvalumab post chemoradiation (PACIFIC) for NSCLC? Report @JTOonline associates CD73 expression and low CD8+ TIL density with poor outcomes. Support for oleclumab? Paired biopsies show role of neoantigen plasticity. https://t.co/1yYvtvjUEV (@StephenVLiu)
9 months ago
Biopsy
|
CD8 (cluster of differentiation 8) • NT5E (5'-Nucleotidase Ecto)
|
CD73 expression
|
Imfinzi (durvalumab) • oleclumab (MEDI9447)
12ms
“In the 3 patients with MSS-CRC or PDAC who had a confirmed response, ≥ 80% of tumor cells expressed CD73” Maybe an abundance of target expression is required for target inhibition to work? Phase 1 of Oleclumab (anti-CD73) + Durvalumab in solid cancers https://t.co/NP3qYM1wH8 (@Aiims1742)
12 months ago
Clinical • Tumor cell
|
NT5E (5'-Nucleotidase Ecto)
|
CD73 expression
|
Imfinzi (durvalumab) • oleclumab (MEDI9447)
1year
Report of oleclumab (anti-CD73) plus osimertinib in #EGFR NSCLC @JTOonline. CD73 often overexpressed in EGFR mutant NSCLC. Explored post 1G/2G TKI, T790M negative, osi naive. At dose level 2, RR 12% with mPFS 7.4m, mOS 25m. https://t.co/we5zEtPi4r (@StephenVLiu)
1 year ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR overexpression • CD73 overexpression • EGFR T790M negative • CD73 expression
|
Tagrisso (osimertinib) • oleclumab (MEDI9447)
over1year
#TumorBoardTuesday I like the logic of 🎯 immunosuppressive molecule (CD73) that can exhaust TILs w concurrent PD-1i. Interestingly, CD73 expression might also pair w better responses to IO: https://t.co/Y0CCZliA1k Excited to see these agents in pancreas and GI cancers too! (@JohnEbbenMDPhD)
over 1 year ago
NT5E (5'-Nucleotidase Ecto)
|
CD73 expression
over3years
Great paper from @AbhiTrip87 @DrChoueiri @BradMcG04 @neerajaiims @LabSignoretti @LaurenCHarshman et al in @jitcancer that offers key insights into where CD73 directed tx may be most useful. Higher grade/stage assoc w inc CD73 - similar expression in ccRCC/nccRCC. (@montypal)
over 3 years ago
CD73 (5'-Nucleotidase Ecto)
|
CD73 expression
over3years
An interesting article highlighted by @jitcancer "Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma" well done to the authors. @LaurenCHarshman @neerajaiims @AbhiTrip87 (@guconnectinfo)
over 3 years ago
CD73 (5'-Nucleotidase Ecto)
|
CD73 expression
over3years
New #JITC article: Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma @LaurenCHarshman @AbhiTrip87 https://t.co/4jw9nrS9rZ (@jitcancer)
over 3 years ago
CD73 (5'-Nucleotidase Ecto)
|
CD73 expression
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login